Steminent Biotherapeutics Inc. (TPEX:7729)

Steminent Biotherapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.94	2.12	51.47
Revenue Growth (YoY)	-	-	-55.63%	-95.88%	-
Cost of Revenue	3.55	6.09	1.98	3.87	22.95
Gross Profit	-3.55	-6.09	-1.04	-1.75	28.52
Selling, General & Admin	45.05	45.83	62.7	25.76	27.23
Research & Development	106.74	110.38	67.73	48.09	44.25
Operating Expenses	151.79	156.21	130.42	73.85	71.47
Operating Income	-155.34	-162.3	-131.46	-75.6	-42.95
Interest Expense	-1.98	-1.92	-1.78	-1.33	-0.79
Interest & Investment Income	3.04	4.13	2.96	0.07	0.03
Currency Exchange Gain (Loss)	1.34	1.34	-0.02	-0.8	-1.82
Other Non Operating Income (Expenses)	-2.66	0.14	1.08	-46.1	-6.02
EBT Excluding Unusual Items	-155.61	-158.6	-129.23	-123.75	-51.56
Gain (Loss) on Sale of Investments	-	-	-	-0.46	-
Gain (Loss) on Sale of Assets	-	-	-	0	-0.01
Pretax Income	-155.61	-158.6	-129.23	-124.2	-51.56
Income Tax Expense	0.15	0.15	-	-	3.65
Net Income	-155.75	-158.75	-129.23	-124.2	-55.21
Net Income to Common	-155.75	-158.75	-129.23	-124.2	-55.21
Shares Outstanding (Basic)	56	56	48	35	30
Shares Outstanding (Diluted)	56	56	48	35	30
Shares Change (YoY)	9.89%	15.42%	37.44%	17.57%	-
EPS (Basic)	-2.77	-2.84	-2.67	-3.52	-1.84
EPS (Diluted)	-2.77	-2.84	-2.67	-3.52	-1.84
Free Cash Flow	-171.27	-226.57	-142.27	-55.71	-31.47
Free Cash Flow Per Share	-3.05	-4.05	-2.94	-1.58	-1.05
Gross Margin	-	-	-110.10%	-82.32%	55.41%
Operating Margin	-	-	-13970.14%	-3564.12%	-83.45%
Profit Margin	-	-	-13733.16%	-5855.78%	-107.27%
Free Cash Flow Margin	-	-	-15119.02%	-2626.69%	-61.14%
EBITDA	-143.52	-158.14	-129.51	-71.91	-35.12
EBITDA Margin	-	-	-	-	-68.23%
D&A For EBITDA	11.82	4.15	1.95	3.69	7.84
EBIT	-155.34	-162.3	-131.46	-75.6	-42.95
EBIT Margin	-	-	-	-	-83.45%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.